Other research analysts also recently issued research reports about the company. Peel Hunt reissued a hold rating on shares of Vectura Group in a research note on Tuesday, September 11th. Citigroup reissued a buy rating and set a GBX 155 ($2.02) target price on shares of Vectura Group in a research note on Monday, September 10th. Shore Capital reissued a hold rating on shares of Vectura Group in a research note on Tuesday, September 11th. Finally, JPMorgan Chase & Co. reissued an overweight rating on shares of Vectura Group in a research note on Wednesday, September 12th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of GBX 127.67 ($1.66).
LON VEC traded down GBX 1.95 ($0.03) during trading on Wednesday, hitting GBX 75.30 ($0.98). 678,973 shares of the company’s stock were exchanged, compared to its average volume of 4,610,000. Vectura Group has a fifty-two week low of GBX 70 ($0.91) and a fifty-two week high of GBX 166.97 ($2.17).
About Vectura Group
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
See Also: What is a Call Option?
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.